en · de · es
nad-notes.peptides3626.com › Topic › Tesamorelin Identity And Structure — Reference Sheet

Tesamorelin Identity And Structure — Reference Sheet

By Editorial Desk · published 2026-02-09 · last reviewed 2026-03-07 · Topic

This is a working overview of HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-03-07. Anything still debated is marked as such rather than presented as settled.

Tesamorelin Identity And Structure

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

Storage Handling and Analytical Methods

Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.

Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.

Tesamorelin at a glance

PropertyValueNotes
Chemical classSynthetic peptideGHRH analog family
Residue count44 amino acidsMatches human GHRH(1-44) backbone
N-terminal grouptrans-3-hexenoylMain structural difference from native hormone
AppearanceWhite to off-white powderLyophilized solid form
Solubility classFreely soluble in waterPeptide character; less soluble in organic solvents

Background and Clinical Development

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

Related pages on this site

Handling, Storage, and Analytical Methods

Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.

Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.

Further detail

The development of insulin therapy has progressed significantly since the early 20th century, starting with animal-derived insulins. In 1922, Frederick Banting and Charles Best successfully used bovine insulin extract to treat humans for the first time. This breakthrough led to the commercial production of bovine insulin in 1923 by Eli Lilly and Company. That same year, Hans Christian Hagedorn founded the Nordisk Insulinlaboratorium in Denmark, which later became Novo Nordisk. In 1926, Nordisk received a Danish charter to produce insulin as a non-profit entity. In 1936, Canadian researchers D.M. Scott and A.M. Fisher developed a zinc insulin mixture, which was licensed to Novo. During this time, Hagedorn discovered that adding protamine to insulin could prolong its action, which led to the development of Neutral Protamine Hagedorn (NPH) insulin in 1946. NPH insulin was marketed by Nordisk in 1950. By 1953, Novo also developed Lente insulin by adding zinc to porcine and bovine insulins, resulting in a longer-acting form. A significant advancement in insulin production occurred in 1978 when Genentech developed the biosynthesis of recombinant human insulin using Escherichia coli bacteria and recombinant DNA technology. This allowed for the production of insulin identical to that produced by the human pancreas. In 1981, Novo Nordisk chemically and enzymatically converted porcine insulin into human insulin. Genentech's synthetic human insulin, produced in partnership with Eli Lilly, was approved by the U.S. Food and Drug Administration in 1982.

In 2010, Latynina criticised the Tagliavini report, saying: "A war, it turns out, is begun by he [sic] who responds to the actions of an aggressor [...]. So when Ossetian 'volunteers' burn Georgian villages - that is not a war. But if they [the Georgians] respond to this, then here you, accursed ones, have started a war." Latynina argued that according to the Tagliavini mission "Georgia had no right to send a single shell into the city [of Tskhinvali]. But the opposite side had a right to burn down Nuli, and that was not an infringement of human rights." Latynina concluded that the commission showed a "cowardice" before "an international hooligan" Vladimir Putin. Latynina called the report "a new Munich Agreement" and stated that "The prevailing motive in the report was to avoid at all costs spoiling relations with Russia". Latynina again criticised Tagliavini for the report during the events in Crimea in 2014, and again in 2015.

Mohs surgery is not suitable for all skin cancers. Mohs micrographic surgery is the most reliable form of margin control; utilising a unique frozen section histology processing technique – allowing for the complete examination of 100% of the surgical margin. The method is unique in that it is a simple way to handle soft, hard-to-cut tissue. It is superior to serial bread loafing at a 0.1 mm interval for improved false negative error rate, requiring less time, tissue handling, and fewer glass slides mounted. The clinical quotes for cure rate of Mohs surgery are from 97% to 99.8% after 5 years for newly diagnosed basal cell cancer, decreasing to 94% or less for recurrent basal cell cancer. Radiation oncologists quote cure rates from 90 to 95% for basal cell cancer less than 1 or 2 cm, and 85 to 90% for basal cell cancer larger than 1 or 2 cm. The Surgical excision cure rate varies from 90 to 95% for wide margins (4 to 6 mm) and small tumors, to as low as 70% for narrow margins and large tumors.

=== 1985 === January 20, 1985 – Ronald Reagan is sworn in for a second term as President of the United States. March 10, 1985 – General Secretary of the Communist Party of the Soviet Union Konstantin Chernenko dies. March 11, 1985 – Soviet Politburo member Mikhail Gorbachev becomes the general secretary of the Communist Party. March 24, 1985 – Major Arthur D. Nicholson, a US Army Military Intelligence officer is shot to death by a Soviet sentry in East Germany. He is listed as the last US casualty in the Cold War.

Sources: en.wikipedia.org

Supporting material

Diabetes was one of the first diseases described, with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine". The Ebers papyrus includes a recommendation for a drink to take in such cases. The first described cases are believed to have been type 1 diabetes. The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Apollonius of Memphis. The disease was considered rare during the time of the Roman Empire, with Galen commenting he had seen only two cases during his career. This is possibly due to the diet and lifestyle of the people of that time, or because the clinical symptoms were only observed during the advanced stage of the disease. Galen named the disease "diarrhea of the urine" (diarrhea urinosa). Indian physicians around the sixth century CE identified the disease and classified it as madhumeha or "honey urine", noting the urine would attract ants. The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to moisture and coldness, reflecting his beliefs in the "Pneumatic School" of medicine. He hypothesized a correlation between diabetes and other diseases, and he discussed differential diagnosis from a snakebite, which also provoked excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.

=== Bacteria === Melatonin is produced by α-proteobacteria and photosynthetic cyanobacteria. There is no report of its occurrence in archaea which indicates that melatonin originated in bacteria most likely to prevent the first cells from the damaging effects of oxygen in the primitive Earth's atmosphere. Novo Nordisk have used genetically modified Escherichia coli to produce melatonin.

==== Structure-based methods ==== Ideally, the structure of a drug target is known, which allows for structure-based pharmacophore modeling. A structure-based model integrates key structural properties of the protein's binding site, such as the spatial distribution of interaction points, with features identified from ligand based pharmacophore models to generate a holistic simulation of the ligand-protein interaction. A major challenge in structure-based modeling is to narrow down pharmacophore features, of which many are initially identified, to a set of high priority features, as modeling too many features is a computational challenge. Another challenge is the incompatibility of pharmacophore modeling with quantitative structure-activity relationship (QSAR) profiling. Accurate QSAR models rely on inclusion of many potential targets, not just the therapeutic target. For example, important pharmacophores may yield high-affinity interactions with therapeutic targets, but they may also lead to undesirable off-target activity, and they may also be substrates of metabolic enzymes, such as Cytochrome P450s. Therefore, pharmacophore modeling against therapeutic targets is only one component of the compound's total structure-activity relationship.

== Robotic platforms == Automated synthesis systems are laboratory robots that combine of software and hardware. As synthesis is a linear combination of steps, the individual steps can be modularized into hardware that accomplishes the specific step (mixing, heating or cooling, product analysis, etc.). Such hardware includes robotic arms that use dispensers and grippers to transfer materials and shakers that adjust the stirring speed and cartesian coordinate system robots that operate on a X Y Z axis and can move items and perform synthesis within designated bounds. Conditions of reactions (atmosphere, temperature, pressure) are controlled with the help of peripherals like: gas cylinders, vacuum pump, reflux system and cryostat. Modular platforms use a variety of tools in order to perform all the unit operations needed in synthesis. There are many commercial modular hardware solutions available to execute synthesis. New software programs are available that can compile an automated synthesis procedure in executable code directly from existing literature. There are also software programs that can retro-synthetically generate a procedure at the level of proficiency of a graduate student.

In April 2022, Collins embarked on her first live theatre tour, titled The GC's Big Night Out. Performing in venues across the UK, the seven-date tour was announced on 19 April 2021 and tickets went on sale on 23 April. The tour was originally scheduled to take place between 15–24 October 2021 but was postponed due to logistical issues surrounding the COVID-19 pandemic. The tour began in Manchester on 5 April 2022 and Collins was joined by Stephen Bailey who assumed the role of presenter. The show featured Collins singing, looking back at her life and career and being interviewed by Bailey before taking questions from the audience. She performed in Glasgow, Southampton, London, Birmingham and Cardiff before the tour concluded in Newcastle on 14 April. In May 2022, Collins was set to take over the role of Matron "Mama" Morton in the UK tour of the musical Chicago. Following the announcement of her casting in March, producer David Ian said "[They] were completely stunned by [Collins'] audition for the role" describing her as "an undeniable force both on and off stage" and that "audiences across the country [were] in for a treat." Collins received criticism from several actors and theatre fans on social media who described her as a "stunt casting". Responding to critics, Collins said she "auditioned for the role and trained really hard" adding that she "didn't just get it because of [her alter ego] the GC".

Sources: en.wikipedia.org

Notes from published material

== Non-surgical alternatives == Lip plumper is a cosmetic product used to make lips appear fuller. These products work by irritating the skin of the lips with ingredients such as capsaicin. This makes the lips swell, temporarily creating the appearance of fuller lips. Suction pumps, a device that uses vacuum pumping to increase blood pressure in the lips, causing temporary swelling.

== Applications == The products based on collagen proteins are used for food, health and nutrition, pharmaceutical industries and technical applications for example Photo, Ballistic, Restoration, Lubricants, Technical detergents.

== Personal life == Culp was married five times: to Elayne Carroll (1951–1956), Nancy Ashe (1957–1966), French actress France Nuyen, whom he met when she guest-starred on I Spy (1967–1970), Sheila Sullivan (1971–1976), and Candace Faulkner (from 1981). In addition to appearing in four episodes of I Spy, two of them written by Culp, in 1969 Nuyen also co-hosted the second episode of the TV comedy Turn-On with him, but the program was never shown, as the series was cancelled after its first airing. Culp had three sons and a daughter with his second wife, and a daughter with his fifth wife. That daughter, producer Samantha Culp, married author Matthew Specktor in 2021.His son Joseph Culp is an actor and director; his son Jason Culp is a voice actor who has narrated many audiobooks. Culp's grandson, Elmo Kennedy O'Connor, is a rapper and performs under the alias Bones. Culp's appearances on The Outer Limits led to a longtime friendship with Harlan Ellison who wrote for the series.

=== Provisions on agriculture === The law rescinds unobligated IRA funding for the Conservation Stewardship Program, Environmental Quality Incentives Program, Agricultural Conservation Easements Program, and Regional Conservation Partnership Program, and adds it to the USDA budget baseline. The OBBBA outlaws climate action-related goals for agriculture. The law also lifts income caps on households that rely on agriculture for more than 75% of their income, potentially empowering corporate farming. The law raises reference prices under the Price Loss Coverage and Agricultural Risk Coverage programs, resulting in $54 billion in additional spending over 10 years. The law increases spending on crop insurance programs by $6.3 billion over 10 years and disaster relief programs at USDA by $2.9 billion in the same timeframe.

Sources: en.wikipedia.org

Frequently asked questions

Is tesamorelin the same as growth hormone?

No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.

What does the trans-3-hexenoyl group do?

It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.

How long is the peptide chain?

The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.

How is the lyophilized powder normally kept?

Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.

Network